The Asia Pacific Companion Diagnostics Market would witness market growth of 21.6% CAGR during the forecast period (2019-2025).
A number of businesses have conducted projects to create biomarker-based therapeutics for other signs of illnesses, including infectious conditions, neurology, and metabolic disorders. Stakeholders in the industry are crafting strategic alliances with the development of diagnostic alternatives for a range of drugs/therapies. Such initiatives focus on enhancing the success rates of clinical trials, thereafter optimizing research and development expenses in the pharmaceutical sector.
In the forecast period, the Asia-Pacific growth rate is anticipated to be highest, mainly owing to increasing demand for personalized medication, the development of health facilities as well as increasing prevalence of different types of cancer that have more unmet needs. The cost efficiency, high sensitivity, and specificity are several main driving factors for market expansion and can be used in simple automated systems. The PCR, which is another important driver of this section, can also determine the sequencing of unknown disease etiologies of many diseases.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
- Neurology and
- Other Indications
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
- South Korea
- Rest of Asia Pacific
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free